Why Celularity Inc.’s (CELU) Stock Is Up 8.45%
As of Tuesday, December 02, Celularity Inc.’s CELU share price has surged by 8.45%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Commentary & Analysis
Why Celularity Inc.’s (CELU) Stock Is Up 18.95%
As of Tuesday, November 25, Celularity Inc.’s CELU share price has surged by 18.95%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Celularity Inc.’s (CELU) Stock Is Down 8.21%
As of Monday, November 03, Celularity Inc.’s CELU share price has dipped by 8.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Celularity Inc.’s (CELU) Stock Is Down 5.50%
As of Wednesday, October 29, Celularity Inc.’s CELU share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Celularity Inc.’s (CELU) Stock Is Down 5.63%
As of Friday, October 17, Celularity Inc.’s CELU share price has dipped by 5.63%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CELU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18.4 | $252.6 | 10% |
|
| Shares Out (Mil) | 28.5 | 52.3 | 36% |
|
| Institutional Ownership | 51.7% | 92.1% | 36% |
|
| Float (Mil) | 18.9 | 40.2 | 28% |
|
| Beta | 0.54 | 0.95 | 30% |
|
| Avg Daily Volume (000s) | 56 | 455 | 29% |
|
| Price Change (52-week) |
(80.5%) | 52.9% | 7% |
|
| Growth | CELU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 13.2% | 13.6% | 68% |
|
| Net Income (5yr) | 15.1% | (9.9%) | 63% |
|
| EPS (5yr) | 49.9% | 16.0% | 93 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (56.9%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CELU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $27 | $38 | 15% |
|
| Net Income (TTM) (Mil) | ($92) | ($43) | 11% |
|
| EPS (TTM) | ($3.586) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $59 | $5 | 40% |
|
| Enterprise Value (Q1) (Mil) | $91 | $180 | 20% |
|
| Valuation | CELU | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CELU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 24.4% | 63.8% | 27% |
|
| Net Margin | (345.4%) | (67.3%) | 3% |
|
| ROA | (76.4%) | (49.8%) | 7% |
|
| ROE | 627.7% | (55.5%) | 100% |
|
| Liabilities to Assets | 135.2% | 30.3% | 97% |
|
| F-Score | 1 | 3 | 1% |
|
Celularity Inc. did not pass any screens on 7/31/2026.
